Profund Advisors LLC Has $917,000 Stock Position in Immunome, Inc. $IMNM

Posted by Geri Gentry on May 22nd, 2026

Profund Advisors LLC raised its stake in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) by 121.7% during the fourth quarter, Holdings Channel reports. The firm owned 42,700 shares of the company’s stock after buying an additional 23,440 shares during the period. Profund Advisors LLC’s holdings in Immunome were worth $917,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Strs Ohio acquired a new stake in Immunome during the fourth quarter valued at approximately $64,000. Assetmark Inc. acquired a new stake in Immunome during the third quarter valued at approximately $39,000. BIT Capital GmbH bought a new position in shares of Immunome in the third quarter valued at approximately $69,000. BNP Paribas Financial Markets raised its stake in shares of Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after acquiring an additional 2,909 shares during the last quarter. Finally, Russell Investments Group Ltd. bought a new position in shares of Immunome in the third quarter valued at approximately $76,000. 44.58% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on IMNM. Craig Hallum lifted their target price on shares of Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Stephens cut their target price on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, March 4th. Leerink Partners cut their target price on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday, May 15th. Truist Financial upgraded shares of Immunome to a “strong-buy” rating in a research note on Monday, May 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $32.82.

Get Our Latest Stock Report on Immunome

Immunome Price Performance

IMNM stock opened at $22.96 on Friday. The company has a 50 day moving average price of $21.94 and a 200 day moving average price of $21.36. Immunome, Inc. has a fifty-two week low of $7.85 and a fifty-two week high of $27.65. The stock has a market capitalization of $2.60 billion, a PE ratio of -9.65 and a beta of 2.11.

Immunome (NASDAQ:IMNM – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. As a group, equities analysts expect that Immunome, Inc. will post -2.26 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Immunome news, CFO Max Rosett sold 65,000 shares of the stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $21.92, for a total value of $1,424,800.00. Following the transaction, the chief financial officer owned 54,037 shares of the company’s stock, valued at approximately $1,184,491.04. This represents a 54.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jean Jacques Bienaime bought 5,000 shares of the business’s stock in a transaction on Friday, May 15th. The stock was bought at an average cost of $20.70 per share, for a total transaction of $103,500.00. Following the purchase, the director directly owned 43,415 shares of the company’s stock, valued at approximately $898,690.50. This trade represents a 13.02% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders sold 139,438 shares of company stock worth $2,964,664. Corporate insiders own 7.21% of the company’s stock.

About Immunome

(Free Report)

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.